Home › Research › Treatments
Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease
Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB, Aizenstien O, Lotan E et al.. Alzheimer's research & therapy, 2025-05-28
Topic: Drug trials: efficacy and safety
Plain-language summary
Results Between July 2023 and January 2025, 169 patients were screened and 86 initiated lecanemab treatment. In the intention-to-treat (ITT) population, MMSE scores declined significantly over 6 months (F(1, 45.13) = 7.41, p =.009). Subgroup analysis revealed a significant decline in younger patients (n = 31; F(1, 24.67) = 8.06, p =.009), but not in older patients (n = 22; F(1, 19.25) = 0.67, p =.424). At 12 months, 31 patients had reached follow-up, with no significant change in MMSE scores observed (F(1, 17.18) = 2.49, p =.133). No significant correlations were found between baseline biomarkers and cognitive change. A mixed-effects model showed no significant effect of ARIA on MMSE change (p =.264) and no interaction with time (p =.433).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bregman, N., Nathan, T., Shir, D., Omer, N., Levy, M. H., David, A. B., et al. (2025). Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-025-01763-1
Vancouver
Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB, et al. Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease. Alzheimer's research & therapy. 2025. doi:10.1186/s13195-025-01763-1. PMID: 40437535.
BibTeX
@article{bregman2025-40437535,
author = {Bregman, N. and Nathan, T. and Shir, D. and Omer, N. and Levy, M. H. and David, A. B. and Aizenstien, O. and Lotan, E. and others},
title = {{Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2025},
doi = {10.1186/s13195-025-01763-1},
pmid = {40437535},
url = {https://doi.org/10.1186/s13195-025-01763-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Between July 2023 and January 2025, 169 patients were screened and 86 initiated lecanemab treatment.
- In the intention-to-treat (ITT) population, MMSE scores declined significantly over 6 months (F(1, 45.13) = 7.41, p =.009).
- Subgroup analysis revealed a significant decline in younger patients (n = 31; F(1, 24.67) = 8.06, p =.009), but not in older patients (n = 22; F(1, 19.25) = 0.67, p =.424).
- At 12 months, 31 patients had reached follow-up, with no significant change in MMSE scores observed (F(1, 17.18) = 2.49, p =.133).
- No significant correlations were found between baseline biomarkers and cognitive change.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Participants31
- Effect size18.6%; 22.1%; 19.8%
- Evidence strengthModerate
How this study scored 71/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 41 of the 58 points we could judge it on, which is 71 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 31 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40437535) |
| Free to read | 2 / 2 | Free to read |
| Points | 41 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 41 of the 58 points we could judge it on is 71 out of 100. |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.